Agilent Technologies Names Massachusetts Eye and Ear Infirmary as Certified Service Provider for Next-Generation Sequencing and aCGH Solutions
SANTA CLARA, Calif., Oct. 24, 2013
Agilent Technologies Inc. (NYSE: A) today announced that the Massachusetts Eye and Ear Infirmary, an affiliate of Harvard Medical School, has been authorized as a Certified Service Provider of Agilent's next-generation target enrichment and microarray-based comparative genomic hybridization (aCGH) solutions. MEEI is home to the medical school's Department of Ophthalmology Ocular Genomics Institute, which is working to harness the power of genomics and gene therapy to advance the knowledge and treatment of blinding eye diseases.
"Becoming an Agilent CSP enables us to provide the ocular genomics research community with access to the latest protocols and technologies we are using at Mass. Eye and Ear with ever-increasing success," said Dr. Eric Pierce, director of the Ocular Genomics Institute. "It is our hope that these tools will help advance studies in genomic research and gene therapy. In addition, incorporating the Agilent Bravo Automated Liquid Handling platform into our service offerings will enable us to quickly process large volumes of samples for even more researchers and for a wide range of genomics applications. We are using these approaches to provide improved clinical genetic diagnostic testing services for patients with inherited eye disorders."
"We are excited to have MEEI as part of the Agilent CSP program," said Victor Fung, senior director of marketing for Agilent's Genomics Solutions Division. "MEEI has used Agilent's NGS target enrichment and aCGH solutions for several years in their retinal degeneration mutational disease research. We look forward to supporting them as they expand their services outside of the Harvard community."
About the Agilent Certified Service Provider Program
Agilent offers its CSP program to select service provider laboratories interested in using its market-leading technologies to provide the highest-quality analysis services to their customers. The company offers two certification paths: Agilent's CGH microarray platform and its upstream target enrichment next-generation sequencing platform. Hands-on training is also provided by field application scientists to ensure customers receive consistent data quality, reproducibility and reliability.
About Massachusetts Eye and Ear Infirmary
Founded in 1824, Massachusetts Eye and Ear Infirmary clinicians and scientists are driven by a mission to find cures for blindness, deafness and diseases of the head and neck. After uniting with Schepens Eye Research Institute, Mass. Eye and Ear in Boston became the world's largest vision and hearing research center, offering hope and healing to patients everywhere through discovery and innovation. Mass. Eye and Ear is a Harvard Medical School teaching hospital and trains future medical leaders in ophthalmology and otolaryngology, through residency as well as clinical and research fellowships. Internationally acclaimed since its founding in 1824, Mass. Eye and Ear employs full-time, board-certified physicians who offer high-quality and affordable specialty care that ranges from the routine to the very complex. U.S. News & World Report's "Best Hospitals Survey" has consistently ranked the Mass. Eye and Ear Departments of Otolaryngology and Ophthalmology as among the top hospitals in the nation.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is the world's premier measurement company and a technology leader in chemical analysis, life sciences, diagnostics, electronics and communications. The company's 20,500 employees serve customers in more than 100 countries. Agilent had revenues of $6.9 billion in fiscal 2012. Information about Agilent is available at www.agilent.com.
# # #
+1 408 553 7093